Peptide Cycling — When to Start, Stop, and Restart

Cycling is about long-term sustainability. Learn when to start, stop, and restart your peptide protocols.

Why Cycling Matters

Most peptides should not be taken indefinitely. The two main reasons for cycling:

• Receptor desensitization: Your body adapts to continuous stimulation. Over time, the same dose produces less effect. Taking breaks allows receptors to resensitize.
• Recovery periods: Even well-tolerated compounds benefit from off periods where your body returns to baseline function.

Typical Cycle Lengths by Category

Healing Peptides (BPC-157, TB-500, GHK-Cu)

• Cycle: 4-8 weeks
• Off period: 2-4 weeks
• Notes: Many users run until the injury resolves rather than a fixed timeline. If healing is complete at week 5, no need to continue to week 8.

GH Secretagogues (CJC-1295, Ipamorelin, Sermorelin)

• Cycle: 12-16 weeks (some run continuously)
• Off period: 4-8 weeks
• Notes: Longer cycles are common because GH axis benefits compound over time. Monitor IGF-1 levels.

Fat Loss Peptides (Semaglutide, Tirzepatide, Retatrutide)

• Cycle: Varies — often 6-12+ months for weight management
• Off period: Taper down, do not stop abruptly
• Notes: GLP-1 agonists require tapering to avoid rebound hunger. Work with a provider on discontinuation.

Cognitive Peptides (Semax, Selank)

• Cycle: 2-4 weeks
• Off period: 2-4 weeks
• Notes: Short cycles prevent tolerance. Many users follow a 3 weeks on / 3 weeks off pattern.

Longevity Peptides (Epithalon)

• Cycle: 10-20 days
• Off period: 4-6 months
• Notes: Epithalon is typically run in short intense bursts, 2-3 times per year.

What to Do During Off Periods

• Continue blood work monitoring
• Maintain your training and nutrition routine
• Track how you feel without the compound — this data is valuable
• Log check-ins in PepOS so you can compare on-cycle vs off-cycle trends
• Plan your next cycle based on what the data showed

Tapering Compounds

Some compounds should be tapered rather than stopped abruptly:

• GLP-1 agonists (Semaglutide, Tirzepatide): Reduce dose by 50% for 2 weeks, then 50% again, then stop. Abrupt cessation can cause rebound appetite and blood sugar spikes.
• Most research peptides (BPC-157, TB-500, CJC-1295): Can be stopped without taper.

Signs You Should End a Cycle Early

• Persistent side effects that do not resolve with dose reduction
• Blood work showing concerning changes (elevated liver enzymes, glucose issues)
• Allergic reaction symptoms
• Goal achieved — continuing adds diminishing returns
• Subjective decline in wellbeing despite good adherence

How PepOS Tracks Cycling

When you set a cycle length in your protocol, PepOS:

• Shows a progress bar (Week X of Y)
• Alerts you as the cycle end date approaches
• Reminds you to get end-of-cycle blood work
• Archives the protocol data so you can compare cycles

Bottom Line

Cycling is about long-term sustainability. Run your protocol for the planned duration, take breaks, monitor blood work, and let PepOS track the data so each cycle is better informed than the last.

---

Ready to start tracking?

Download PepOS on the iOS App Store to track your protocols, monitor your vial inventory, and sync your actual recovery data with Apple Health.

Educational content only. Not medical advice. Consult a healthcare professional before starting any protocol.